RYVU THERAPEUTICS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.3 PLN | -1.00% |
|
-6.81% | -14.26% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 718.7 | 903.1 | 1,120 | 1,139 | 1,329 | 1,140 | - | - |
| Enterprise Value (EV) 1 | 718.7 | 744.3 | 1,042 | 1,139 | 1,329 | 1,066 | 1,158 | 1,140 |
| P/E ratio | - | -26 x | -14.4 x | -10.7 x | -14.3 x | -12.3 x | -11 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 19.4 x | 24.4 x | 30.2 x | 16.6 x | 19.8 x | 7.51 x | 5.24 x | - |
| EV / Revenue | 19.4 x | 20.1 x | 28.1 x | 16.6 x | 19.8 x | 7.02 x | 5.32 x | - |
| EV / EBITDA | - | -31.9 x | -15.9 x | -17.4 x | -14.8 x | -12.9 x | -35.1 x | - |
| EV / FCF | - | -11.2 x | -14.9 x | - | - | -8.08 x | -11.5 x | -950 x |
| FCF Yield | - | -8.95% | -6.71% | - | - | -12.4% | -8.67% | -0.11% |
| Price to Book | - | 4.04 x | 6.61 x | - | - | 8 x | 24.7 x | - |
| Nbr of stocks (in thousands) | 15,971 | 18,355 | 18,355 | 23,120 | 23,120 | 23,120 | - | - |
| Reference price 2 | 45.00 | 49.20 | 61.00 | 49.25 | 57.50 | 49.30 | 49.30 | 49.30 |
| Announcement Date | 4/9/20 | 3/16/21 | 3/15/22 | 3/24/23 | 3/13/24 | - | - | - |
1PLN in Million2PLN
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 37 | 36.95 | 37.08 | 68.44 | 67.3 | 151.8 | 217.5 | - |
| EBITDA 1 | - | -23.31 | -65.31 | -65.52 | -89.98 | -82.6 | -33 | - |
| EBIT 1 | - | -35.67 | -77.87 | -78.42 | -100.9 | -160 | -93.6 | - |
| Operating Margin | - | -96.53% | -210% | -114.59% | -150.01% | -105.38% | -43.03% | - |
| Earnings before Tax (EBT) 1 | - | -30.62 | -77.42 | -79.2 | -92.11 | -161.2 | -118.6 | - |
| Net income 1 | - | -31.69 | -77.53 | -83.78 | -92.11 | -161.2 | -118.6 | - |
| Net margin | - | -85.76% | -209.1% | -122.42% | -136.88% | -106.17% | -54.54% | - |
| EPS 2 | - | -1.890 | -4.224 | -4.600 | -4.020 | -4.000 | -4.500 | - |
| Free Cash Flow 1 | - | -66.58 | -69.85 | - | - | -132 | -100.4 | -1.2 |
| FCF margin | - | -180.18% | -188.38% | - | - | -86.9% | -46.18% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 4/9/20 | 3/16/21 | 3/15/22 | 3/24/23 | 3/13/24 | - | - | - |
1PLN in Million2PLN
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 34.62 | 18.32 | 15.25 | 16.24 | 17.71 | 24.5 |
| EBITDA 1 | - | 2.242 | -11.55 | -24.61 | - | -24.29 | -17.3 |
| EBIT 1 | - | -0.6844 | -18.1 | -31.64 | - | -26.92 | -20.25 |
| Operating Margin | - | -1.98% | -98.84% | -207.43% | - | -152% | -82.65% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - |
| Net income 1 | -11.8 | -8.525 | -17.6 | -28.51 | -18.25 | -27.75 | -17.8 |
| Net margin | - | -24.63% | -96.07% | -186.88% | -112.42% | -156.74% | -72.65% |
| EPS | -0.6430 | - | - | - | -0.7900 | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/23/22 | 3/24/23 | 5/16/23 | 9/13/23 | 11/29/23 | 3/13/24 | - |
1PLN in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 18.4 | - |
| Net Cash position 1 | - | 159 | 78.2 | - | - | 73.6 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.558 x | - |
| Free Cash Flow 1 | - | -66.6 | -69.8 | - | - | -132 | -100 | -1.2 |
| ROE (net income / shareholders' equity) | - | - | -39.4% | - | - | -39.9% | -29.5% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 12.20 | 9.230 | - | - | 6.160 | 1.990 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 34.2 | - | - | - | 6.45 | 9.2 | 14.4 |
| Capex / Sales | - | 92.5% | - | - | - | 4.25% | 4.23% | - |
| Announcement Date | 4/9/20 | 3/16/21 | 3/15/22 | 3/24/23 | 3/13/24 | - | - | - |
1PLN in Million2PLN
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
49.3
PLN
Average target price
73.12
PLN
Spread / Average Target
+48.33%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.26% | 282M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RVU Stock
- Financials Ryvu Therapeutics S.A.
